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Abstract
Human metapneumovirus (hMPV) is a widely distributed pathogen responsible for acute
upper and lower respiratory infections of varying severity. Previously, we reported that N-
sulfonated derivatives of poly(allylamine hydrochloride) (NSPAHs) efficiently inhibit replica-
tion of the influenza virus in vitro and ex vivo. Here, we show a dose dependent inhibition of
hMPV infection by NSPAHs in LLC-MK2 cells. The results showed strong antiviral proper-
ties of NSPAHs. While the activity of NSPAHs is comparable to those of carrageenans, they
show better physicochemical properties and may be delivered at high concentrations. The
functional assays showed that tested polymers block hMPV release from infected cells and,
consequently, constrain virus spread. Moreover, further studies on viruses utilizing different
egress mechanisms suggest that observed antiviral effect depend on selective inhibition of
viruses budding from the cell surface.
Introduction
Human metapneumovirus (hMPV) is associated with acute infections of the respiratory tract,
with increased severity in children, infants, elderly, and immunocompromised patients [1–4].
hMPV was identified in 2001 in the Netherlands [5] and sorted to the Pneumoviridae family.
Its prevalence in children and infants requiring hospitalization worldwide reaches 4–25%
[6,7]. Moreover, serological studies showed that ~70% of children are seropositive at the age of
five [8]. Symptoms associated with the infection are usually mild (e.g., cough, subfebrile tem-
perature), but more severe disease also occurs (e.g., bronchitis, pneumonia) [9,10].
hMPV F protein utilizes heparan sulfate (HS), a negatively charged glycosaminoglycan
(GAG) present on the cellular membrane, as an attachment factor [11]. Previous studies have
shown that natural polysaccharides containing sulfonate groups efficiently inhibit infections
caused by viruses employing HS during cell entry [12–19] and it was proposed that carrageen-
ans inhibit the attachment of the hMPV to HS by interacting with the F protein [19]. It is,
PLOS ONE | https://doi.org/10.1371/journal.pone.0214646 March 28, 2019 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Ciejka J, Botwina P, Nowakowska M,
Szczubiałka K, Pyrc K (2019) Synthetic sulfonated
derivatives of poly(allylamine hydrochloride) as
inhibitors of human metapneumovirus. PLoS ONE
14(3): e0214646. https://doi.org/10.1371/journal.
pone.0214646
Editor: Ian B Hogue, Arizona State University,
UNITED STATES
Received: January 23, 2019
Accepted: March 18, 2019
Published: March 28, 2019
Copyright: © 2019 Ciejka et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: This work was supported by grants from
the National Science Center (UMO- 2012/07/E/NZ6/
01712 and UMO-2016/21/D/ST5/01661) (KP and
JC, respectively), grant Lider/27/55/L-2/10/2011
(to KP) from the National Centre for Research and
Development, Foundation for Polish Science
provided funding to JC under grant number
VENTURES/2013-11/1 cofinanced by the EU
however, worth to mention that replication of some HS independent viruses is also hampered
in the presence of these polymers [20–23]. Currently, in some countries, ι-carrageenan is the
main component of nasal spray used to prevent respiratory viral infections [24,25].
In our previous report we showed that N-sulfonated derivatives of poly(allylamine) hydro-
chloride (NSPAHs) effectively inhibit influenza virus in vitro and ex vivo by inhibition of
virion release from infected cells [26]. Surprisingly, we showed that new compounds share the
mechanism of action with ι-carrageenan, and it is very different from previously proposed.
Although the antiviral activity of NSPAHs is comparable to the one observed for carrageenans,
physicochemical properties of NSPAHs seem to be superior [27].
The aim of this study was to examine the anti-hMPV activity of NSPAHs. For this, a series
of in vitro experiments were conducted. Two NSPAH derivatives were selected for the study:
NSPAH-15-94 (molecular mass (Mw) of 15 kDa, degree of substitution with sulfonate groups
(DS) of 94%) and NSPAH-65-96 (Mw = 65 kDa, DS = 96%), as these were the most potent
inhibitors of hMPV replication in the preliminary studies. As reference, two sulfonated poly-
saccharides with well-established antiviral properties (ι-carrageenan, and λ-carrageenan) were
used.
Materials and methods
Polymers
NSPAH-15-94 and NSPAH-65-96 were synthesized, analyzed and purified by dialysis as
described before [26]. The purification process was carried out against deionized water for 1
week (molecular mass cutoff of 14 kDa). Afterward, the water was removed by freeze drying to
give the product as pale-yellow crystals. Iota carrageenan (ι-car) and lambda carrageenan (λ-
car) were obtained from Sigma-Aldrich, Poland.
Cell culture
Rhesus monkey kidney epithelial cells (LLC-MK2, ATCC CCL-7) were maintained in minimal
essential medium (MEM) containing 1 part of Earle’s MEM and two parts of Hanks MEM
(Thermo Scientific, Poland) supplemented with 3% heat-inactivated fetal bovine serum (FBS;
PAA Laboratories, Austria), penicillin (100 U/ml) and streptomycin (100 μg/ml) (Sigma-
Aldrich, Poland). Cells were propagated in T75 flasks (TPP, Switzerland) at 37˚C in atmo-
sphere containing 5% CO2.
Virus preparation, titration and infection
hMPV virus stock (clinical isolate, clade B2) was kindly provided by Dr. Oliver Schildgen
(Institute of Pathology, Witten/Herdecke University). hMPV A1 virus stock (strain: NL/1/00)
was acquired from the European Virus Archive (011V-00930). Viruses were propagated as
described before [28]. Human coronavirus NL63 (HCoV-NL63) stock was prepared as
described before [17]. All assays were carried out using fully confluent LLC-MK2 (1.5 × 104
cells per well) cultured for 48 h on 96-well plates (TPP, Switzerland). Cells were infected with
virus at TCID50 (50% tissue culture infectious dose) of 400 per ml (MOI = 0.05) in 0% DMEM
(Dulbecco’s Modified Eagle’s Medium (Thermo Scientific, Poland) deprived of FBS, supple-
mented with penicillin (100 U/ml), streptomycin (100 μg/ml), gentamicin (50 μg/ml), ampho-
tericin (2.5 μg/ml) and trypsin (1 μg/ml) (Sigma-Aldrich, Poland)). Virus titers were assessed
as described by Reed and Muench [28,29].
Novel hMPV inhibitors
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XTT assay
Cell viability was evaluated using XTT Cell Viability Assay kit (Biological Industries, USA)
according to the manufacturer’s instructions. Cells were incubated with tested polymers for 6
days at 37˚C in atmosphere containing 5% CO2. After incubation, the medium was discarded,
cells were rinsed with phosphate-buffered saline (PBS) and 100 μl of fresh medium was added
to each well. Next, 50 μl of the activated 2,3-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetra-
zolium-5-carboxanilide (XTT) solution was added and samples were incubated for 2 h at
37˚C. The absorbance (λ = 450 nm) was measured using Spectra MAX 250 spectrophotometer
(Molecular Devices, USA).
Quantitative real-time PCR
Virus yield was determined by reverse transcription (RT) quantitative real-time PCR (qPCR).
To ensure that polymers do not affect the isolation and/or amplification the template, superna-
tants were diluted 1000 times and total RNA was isolated with Viral DNA/RNA kit (A&A Bio-
technology, Poland) in accordance with the manufacturer’s instructions. Reverse transcription
reaction was carried out with a high-capacity cDNA reverse transcription kit (Thermo Scien-
tific, Poland) according to the manufacturer’s instructions. qPCR was performed with RT
HS-PCR Mix Probe (A&A Biotechnology, Poland), as described before [28,30] (hMPV: prim-
ers (450 nM each) 50 GCT GTC AGC TTC AGT CAA TTC AA 30 and 50 GTT ATC CCT
GCA TTG TCT GAA AAC T 30; probe (100 nM): 50 6-FAM-CGC ACA ACA TTT AGG
AAT CTT CT-MGB 30. HCoV-NL63: primers (450 nM each) 50-AAA CCT CGT TGG
AAG CGT GT-30 and 50-CTG TGG AAA ACC TTT GGC ATC-30; probe (100 nM): 50-
FAM-ATG TTA TTC AGT GCT TTG GTC CTC GTG AT-TAMRA-3). The number of
virus copies was determined using a series of 10-fold diluted DNA standards containing a
known number of template copies. The reaction was carried out as follows: 2 min at 50˚C,
10 min at 92˚C, followed by 40 cycles of 15 s at 92˚C and 1 min at 60˚C. For each virus a stan-
dard curve was prepared separately. The lower limit of detection was 103 viral RNA copies per
milliliter.
Replication inhibition assay
To study antiviral properties of the compounds, cells were infected with hMPV or inoculated
with the mock sample in the presence or absence of polymer. After 2 h infection at 37˚C, unab-
sorbed hMPV virions were removed by rinsing cells thrice with PBS. Subsequently, media sup-
plemented with inhibitors were added and cultures were incubated for 6 days at 37˚C. After
incubation, culture supernatants were analyzed by titration and by RT-qPCR, as described
above.
Mechanism of action
To study the mechanism of action of tested polymers, a battery of functional assays were con-
ducted as described before [26], with some modifications.
Virus inactivation assay
The assay shows the influence of tested compounds on the viral particle; polymers at a final
concentration of 1000 μg/ml were mixed with virus stock and incubated for 1 h at room tem-
perature while mixing at 1000 rpm. hMPV stock incubated in the absence of the polymer
was treated as a control. After incubation, samples were diluted 200 times to ensure that the
Novel hMPV inhibitors
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polymer concentration is below the lower limit of the effective range. Samples were titrated as
described by Reed and Muench [29].
Cell protection assay
The assay shows the effect of polymers on the cell; a confluent culture of LLC-MK2 cells was
inoculated with 100 μl of polymer solution (1000 μg/ml) per well. Samples were incubated at
37˚C for 2 h, media were removed, and 100 μl virus or mock solution (MOI = 0.05) was added
to each well. After 2 h incubation at 37˚C media were discarded and cells were rinsed thrice
with PBS to remove residual virus particles. Then, 100 μl of fresh medium was added to each
well and plate was incubated for 6 days at 37˚C.
Virus attachment assay
The assay allows to examine the effect of the compound on the virus-receptor interaction; a
confluent culture of LLC-MK2 cells was pre-cooled to 4˚C and overlaid with 100 μl of media
supplemented with tested polymer (1000 μg/ml) and virus (MOI = 0.05) or mock control. The
samples were incubated at 4˚C for 1 h to allow virus attachment but to block virus internaliza-
tion [31]. After incubation, cells were rinsed thrice with ice-cold PBS to remove residual virus
particles. Then, 100 μl of fresh medium was added and cells were incubated for 6 days at 37˚C.
Virus internalization assay
The assay allows to evaluate virus entry into the susceptible cell. Pre-cooled (4˚C) confluent
cells were infected with hMPV at MOI of 0.05 or treated with mock. The plate was incubated
for 2 h at 4˚C to allow virus attachment, but not internalization. Supernatants were discarded
and cells were washed thrice with ice-cold PBS to remove unbound virus particles. Next,
100 μl of media supplemented with polymers (1000 μg/ml) was added and cells were incubated
for 2 h at 37˚C to allow virus internalization. Finally, the supernatants were discarded, cells
were washed with an acidic buffer (pH 3.0, 0.1 M glycine, 0.1 M sodium chloride) to inactivate
particles that did not enter the cell. Cultures were incubated for 6 days at 37˚C in medium
deprived of polymers.
Virus replication, assembly and egress assay
The assay eEvaluates virus replication and production of infectious progeny. Confluent cells
were incubated with 100 μl of the hMPV at MOI of 0.05. The infection was carried out for 2 h
at 37˚C. Subsequently, medium was discarded and cultures were rinsed thrice with PBS. Cells
were overlaid with media supplemented with polymers or control samples and incubated for 6
days at 37˚C. In this test, both supernatants and cell lysates were analyzed. Lysates were pre-
pared by 3 fast cycles of freezing and thawing at -80˚C in R9F buffer (A&A Biotechnology,
Poland).
Confocal microscopy
For confocal microscopy analysis, replication inhibition assay was performed on cells seeded
on coverslips in 6-well plates (TPP, Switzerland). Subsequently, cells were washed with PBS,
fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated for 2
h with 5% bovine serum albumin (BSA) containing 0.1% Tween 20 (Sigma-Aldrich, Poland).
Subsequently, cells were incubated for 2 h with 1 μg/ml mouse anti-hMPV F-protein antibody
(Ingenasa, Spain). Then, cells were incubated for 1 h with 2.5 μg/ml Alexa Fluor 488-labeled
goat anti-mouse antibody (Molecular Probes, USA). Nuclear DNA was stained with DAPI
Novel hMPV inhibitors
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(0.1 μg/ml, Sigma-Aldrich, Poland). Fluorescent images were acquired with a Nikon Eclipse
Ti-E confocal microscope under NIS-Elements—Microscope Imaging Software (Nikon
Instruments Europe B.V., Amsterdam, The Netherlands).
Statistical analysis
All experiments were conducted at least in triplicate. The results are expressed as means ±
standard deviations (SD). The 50% inhibitory concentration (IC50) values were calculated
using the Graph Pad Prism function. To determine the significance of the results obtained,
Student t-test was used and P values< 0.05 were considered significant. Virus yields and virus
titers are presented as normalized data, i.e., log reduction values (LRVs) [26] for easier com-
parison of the inhibitory effect between assays. LRV was calculated according to the following
formula: LRV = log (ci/c0) where ci is the number of viral RNA copies per milliliter in the sam-
ple treated with inhibitor and c0 is the number of viral RNA copies per milliliter in control
sample (untreated cells). Raw research data (number of copies per milliliter or TCID50 values)
are presented in supporting information file.
Results and discussion
Cytotoxicity of polymers on LLC-MK2 cells
The cells were incubated for 6 days in the presence or absence of evaluated compound, and the
cell viability was assessed using an XTT assay. While some cytotoxicity was observed for ι-car
Fig 1. Sulfonated polymers are not toxic for cells at effective concentration range. The cytotoxicity of the tested polymers (ι-car: ι-carrageenan, λ-
car: λ-carrageenan) determined by XTT assay. Values that are significantly different (P< 0.05) from the control are indicated by an asterisk. All
experiments were performed in triplicate. Average values with standard deviations (error bars) are presented.
https://doi.org/10.1371/journal.pone.0214646.g001
Novel hMPV inhibitors
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Fig 2. Sulfonated polymers hamper hMPV B2 infection. Inhibition of the infection was evaluated using RT-qPCR (A) and
virus titration (B). Polymers were present during the whole infection process. Data are shown as log reduction values (LRVs)
normalized to the control samples. All experiments were performed in triplicate. The results are presented as average values
with standard deviations (error bars). An asterisk (P< 0.05) indicates values that are significantly different from the control.
ι-car: ι-carrageenan, λ-car: λ-carrageenan.
https://doi.org/10.1371/journal.pone.0214646.g002
Novel hMPV inhibitors
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and NSPAH-65-96 at 5000 μg/ml (~80% of the control), at lower concentrations the viability
of cells was not affected (Fig 1). Obtained results are consistent with previously published data
[26].
NSPAHs and carrageenans inhibit hMPV replication in vitro
In the initial experiment, polymers were tested for their ability to hamper hMPV replication in
LLC-MK2 cells. Cells were overlaid with media supplemented with polymers or control
Fig 3. Sulfonated polymers limit the number of infected cells. NSPAHs and carrageenans inhibit viral infection by hampering virus release from
infected cells. Fluorescence images of LLC-MK2 cells (nuclei in blue) infected with hMPV B2 (green) were collected 5 days p.i. (scale bar = 100 μm).
https://doi.org/10.1371/journal.pone.0214646.g003
Novel hMPV inhibitors
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samples and hMPV or mock samples. Polymers were present during whole experiment. All
compounds suppressed virus replication (RT-qPCR) by at least 2 log units at 1000 μg/ml, with
IC50 values of 231 μg/ml, 236 μg/ml, 117 μg/ml, 166 μg/ml for ι-car, λ-car, NSPAH-15-94, and
NSPAH-65-96, respectively (Fig 2A; S1 Fig). To test if infectivity of progeny virus is also
diminished, cell culture supernatants were titrated. As visible in Fig 2B, NSPAH-15-94 exhibits
the best antiviral properties. Confocal imaging confirmed this observation, as in the presence
of the polymers the number of infected cells was lower compared to the control (Fig 3).
To ensure broad specificity of NSPAH towards different hMPV strains, the study was per-
formed also using different hMPV strain (clade A1). Similar antiviral effect was observed (Fig
4; S8 Fig).
NSPAHs and carrageenans hamper release of progeny virions from
infected cells
In the next step, we aimed to elucidate the mechanism of action for described polymers. At
1000 μg/ml no inhibition of early steps of virus infection was noted for carrageenans or
NSPAHs (first four functional assays, S4–S7 Figs), but we observed strong inhibition of prog-
eny virus production in assay 5, wherein the inhibitors were added 2 h after the inoculation.
All tested compounds inhibited hMPV progeny virus production, as illustrated by decreased
virus yields and titers (p< 0.05). RT-qPCR analysis indicated that the inhibition is the most
Fig 4. Sulfonated polymers hamper hMPV A1 infection. Inhibition of the infection was evaluated using RT-qPCR (black bars) and virus titration
(grey bars). Polymers (1000 μg/ml) were present during the entire hMPV replication cycle. Data are shown as log reduction values (LRVs) normalized
to the control samples. All experiments were performed in triplicate. The results are presented as average values with standard deviations (error bars).
An asterisk (P< 0.05) indicates values that are significantly different from the control. ι-car: ι-carrageenan, λ-car: λ-carrageenan.
https://doi.org/10.1371/journal.pone.0214646.g004
Novel hMPV inhibitors
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profound (ca. 3 log units) for ι-car and NSPAH-15-94 (Fig 5, black bars; S2 Fig). Titration of
supernatants revealed that all compounds inhibited production of hMPV infectious virions by
ca. 2 log units (Fig 5, grey bars; S2 Fig). Obtained results suggest that tested polymers hamper
late stages of virus replication cycle, after the virus enters the cell. To further investigate the
mechanism, supernatants from infected cultures were discarded and cells were lysed by three
freeze and thaw cycles (titration) or with lysis buffer (RNA isolation). Surprisingly, RT-qPCR
analysis revealed only minor inhibition (p< 0.05) of viral RNA replication by carrageenans
and no inhibitory activity for NSPAHs (Fig 6, black bars; S3 Fig). This is consistent with our
previous results on the influenza virus [26]. In the case of titration, we observed slight but sig-
nificant increase in the infectivity of the samples in case of ι-car and NSPAH-65-96. NSPAH-
15-94 also increase the infectivity of cell lysates, however, this increase was statistically non-sig-
nificant (Fig 6, grey bars; S2 Fig). This indicates that hMPV virions correctly progress to the
budding stage, but in the presence of the polymers they remain cell-associated. Altogether,
obtained data indicate that NSPAHs do not affect virus replication per se, but lock them on
cells and limit their spread to the neighboring cells.
While some previous reports suggest inhibition of early stages of viral replication by carra-
geenans [19], we were not able to replicate these results. It is, however, possible that the mecha-
nism of action may very depending on the origin of these natural polymers [15,20,21,26].
Fig 5. Inhibition of hMPV B2 replication by sulfonated polymers during late steps of the virus replication cycle. Inhibition of the infection was
evaluated using RT-qPCR (black bars) and virus titration (grey bars). Polymers (1000 μg/ml) were added after infection of LLC-MK2 cells with hMPV
for 2 h and supernatants were collected 6 days p.i. Data are shown as log reduction values (LRVs) normalized to the control samples. All experiments
were performed in triplicate. The results are presented as average values with standard deviations (error bars). An asterisk (P < 0.05) indicates values
that are significantly different from the control. ι-car: ι-carrageenan, λ-car: λ-carrageenan.
https://doi.org/10.1371/journal.pone.0214646.g005
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To study whether the observed antiviral effect is virus-specific, the same cell line was
infected with an unrelated virus, i.e., human coronavirus NL63 (HCoV-NL63). This virus effi-
ciently replicates in LLC-MK2 cells but is released from the cell in a different mechanism. In
contrast to hMPV and influenza A viruses, which bud from the cell surface, HCoV-NL63 buds
from the Golgi apparatus and mature infectious viral particles are transported via exocytosis to
the cell surface [32]. None of the tested polymers inhibited HCoV-NL63 (Fig 7; S9 Fig). This
observation suggests that the polymers block virus release from the cell surface, e.g., by modifi-
cation of membrane plasticity or anchoring the progeny virions to the cell. One may also con-
sider that the difference in NSPAHs activity between hMPV and HCoV-NL63 results from
different requirements for the HSPGs presence, but it would not explain strong inhibitory
effect of NSPAHs against the influenza virus. Moreover, HCoV-NL63 was also shown to
employ HSPGs during the entry to the cell [33].
Conclusions
To sum up, we demonstrated a dose-dependent inhibition of hMPV replication by sulfonated
poly(allylamine)-based polymers. Among tested polymers, ι-carrageenan and NSPAH-15-94
show the strongest antiviral properties against hMPV. Studies on the mechanism of anti-
Fig 6. Sulfonated polymers do not inhibit intracellular hMPV B2 replication. Inhibition of intracellular hMPV replication was tested using RT-
qPCR (black bars) or titration (grey bars). Polymers (1000 μg/ml) were added 2 h after infection of LLC-MK2 with hMPV and lysates were prepared 6
days p.i. Data are shown as log reduction values (LRVs) normalized to the control samples. All experiments were performed in triplicate. The results are
presented as average values with standard deviations (error bars). An asterisk (P< 0.05) indicates values that are significantly different from the control.
ι-car: ι-carrageenan, λ-car: λ-carrageenan.
https://doi.org/10.1371/journal.pone.0214646.g006
Novel hMPV inhibitors
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hMPV properties of tested polymers imply that the decrease of samples’ infectivity is due to
blocking virus release from the cellular membrane.
Developed synthetic polymers are not toxic and offer similar antiviral properties as carra-
geenans but show better physicochemical properties. In our previous work we reported that
NSPAHs hamper influenza virus replication in vitro and in vivo and we believe that they may
be considered as broad-spectrum drug candidates competitive to marketed compounds.
Supporting information
S1 Fig. Polymers hamper hMPV B2 infection.
(PDF)
S2 Fig. Inhibition of human metapneumovirus B2 virus (hMPV) replication in LLC-MK2
cells on late steps of virus replication.
(PDF)
S3 Fig. Polymers inhibit releasing step of the hMPV replication cycle.
(PDF)
S4 Fig. Virus inactivation assay (1).
(PDF)
S5 Fig. Virus adsorption assay (2).
(PDF)
S6 Fig. Virus attachment assay (3).
(PDF)
Fig 7. Sulfonated polymers do not inhibit HCoV-NL63 infection. Inhibition of the infection was evaluated using
RT-qPCR (black bars) and virus titration (grey bars). Polymers (1000 μg/ml) were present throughout the infection.
Data are shown as log reduction values (LRVs) normalized to the control samples. All experiments were performed in
triplicate. The results are presented as average values with standard deviations (error bars). An asterisk (P< 0.05)
indicates values that are significantly different from the control. ι-car: ι-carrageenan, λ-car: λ-carrageenan.
https://doi.org/10.1371/journal.pone.0214646.g007
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S7 Fig. Virus internalization assay (4).
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S8 Fig. Sulfonated polymers hamper hMPV A1 infection.
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S9 Fig. Sulfonated polymers do not inhibit HCoV-NL63 infection.
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